

1 **Morbidity associated with *Schistosoma mansoni* infection in northeastern**
2 **Democratic Republic of the Congo**

3 Maurice M Nigo^{1, 2, 3, 4}, Peter Odermatt^{3, 5}, David Wully Nigo⁶, Georgette B. Salieb-Beugelaar^{1, 2, 3},
4 Manuel Battegay^{3, 7}, Patrick R Hunziker^{1, 2, 3} *

5
6 **1** Nanomedicine Translation Group, Medical Intensive Care Clinic, University Hospital Basel
7 University of Basel, Petersgraben 4, CH-4031 Basel, Switzerland; **2** CLINAM - European
8 Foundation for Clinical Nanomedicine, Alemannengasse 12, P.O. Box, CH-4016 Basel,
9 Switzerland; **3** University of Basel, Petersplatz 1, Basel, Switzerland; **4** Institut Supérieur des
10 Techniques Médicales (ISTM) Nyankunde, B.P. 55 Bunia, Democratic Republic of Congo **5** Swiss
11 Tropical and Public Health Institute, Socinstrasse 57, P.O. Box, CH-4002 Basel, Switzerland; **6**
12 Centre Hospitalier, Ingbokolo Town, Democratic Republic of Congo; **7** Department of Infectiology
13 & Hospital Hygiene, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland.

14

15 **Short title:** Schistosomiasis morbidity burden in Ituri province in northeastern Congo

16 * corresponding author: patrick.hunziker@usb.ch

17

18 **Abstract**

19 **Background**

20 Controlling morbidity is the main target of schistosomiasis control. Yet, only rarely do we assess
21 morbidity linked to *Schistosoma* sp. infection. In the Democratic Republic of Congo (DRC), and
22 particularly in the northeastern Ituri province, morbidity associated with *Schistosoma mansoni*
23 infection is unknown. For this reason, we aimed to assess intestinal and hepatosplenic morbidity
24 associated with *S. mansoni* infection in Ituri province.

25 **Methods / Principal Findings**

26 In 2017, we conducted a cross-sectional study in 13 villages in Ituri province, DRC. *S. mansoni*
27 infection was assessed with a Kato-Katz stool test (2 smears) and a point-of-care circulating
28 cathodic antigen (POC-CCA) test in urine. A questionnaire was used to obtain demographic data
29 and information about experienced intestinal morbidity. Each participant underwent an abdominal
30 ultrasonography examination to diagnose hepatosplenic morbidity. Of the 586 study participants,
31 76.6% tested positive for *S. mansoni*. Intestinal morbidity, such as abdominal pain (52.7%),
32 diarrhoea (23.4%) and blood in the stool (21.5%) in the previous two weeks, was very frequent, as
33 was hepatosplenic morbidity, such as splenomegaly (60.1%), hepatomegaly (23.2%) and abnormal
34 liver parenchyma pattern (52.6%). Hepatomegaly (adjusted odds ratio [aOR] 2.04, 95% confidence
35 interval [CI] 1.27–3.26, $P=0.003$) and splenomegaly (aOR 1.69, 95% CI 1.17–2.45, $P=0.005$) were
36 positively associated with *S. mansoni* infection at the individual level. At the village level, *S.*
37 *mansoni* prevalence was positively associated with the prevalence of hepatomegaly and
38 splenomegaly. Higher *S. mansoni* infection intensities were associated with diarrhoea, blood in the

39 stool, hepatomegaly, splenomegaly and with liver parenchyma, pathology pattern D-E. Four study
40 participants were diagnosed with ascites and five reported hematemesis.

41 **Conclusions/Significance:** Our study documents a high burden of intestinal and hepatosplenic
42 morbidity associated with *S. mansoni* infection status in Ituri province. The results call for targeted
43 interventions to address both *S. mansoni* infection and related morbidity.

44 **Keywords:** *Schistosoma mansoni*; Ituri province; Democratic Republic of Congo; infection
45 prevalence; infection intensity; hepatosplenic morbidity

46

47 **Author Summary**

48 Schistosomiasis caused by *Schistosoma mansoni* is of great public health importance in sub-
49 Saharan Africa. The World Health Organisation (WHO) recommends that control efforts aim to
50 reduce morbidity through large scale intervention programmes. However, intestinal and liver
51 morbidity is rarely assessed in such control programmes. Hence, little is known about (i) the
52 magnitude of the intestinal and liver morbidity burden in a given community, or about (ii) the
53 morbidity associated with *S. mansoni* infection, specifically. We conducted a (cross-sectional)
54 study in which we assessed intestinal morbidity by questionnaire and liver morbidity by abdominal
55 ultrasonography. Further, we determined the infection status of the study participants using
56 standard diagnostic procedures (Kato-Katz technique and point-of-care cathodic circulating *S.*
57 *mansoni* antigen [POC-CCA] test in urine). Among 586 study participants, six years and older,
58 from 13 villages in Ituri province, DRC, we observed a high degree of intestinal (e.g. 23.4% with
59 diarrhoea, 21.5% with blood in stool) and hepatosplenic morbidity (e.g. 60.1% with enlarged
60 spleen, 23.2% with enlarged liver). *S. mansoni* infection was associated with liver and spleen
61 enlargement. Likewise, *S. mansoni* infection intensity was linked to diarrhoea, to liver and spleen
62 enlargement and to pathological changes in the liver parenchyma. At village level, we observed
63 that the prevalence of enlarged liver and spleen among patients increased with the prevalence of *S.*
64 *mansoni* infection. We conclude that the population of Ituri province carries an alarming burden of
65 intestinal, liver and spleen morbidity associated with *S. mansoni* infection. Therefore, a
66 comprehensive control programme to address this infection and disease burden is urgently
67 required.

68

69 **Introduction**

70 Schistosomiasis is a neglected tropical disease (NTD) caused by several *Schistosoma* species.
71 Chronic infection may result in damage to multiple organs, depending on the species and other
72 factors, such as infection intensity. The adult worm of *Schistosoma mansoni* dwells in portal veins.
73 The daily migration to the mesenteric veinlets that drain the intestines are used to deposit the eggs.
74 Eggs release enzymes that provoke inflammation, which in turn facilitates the transition of the egg
75 into the intestinal lumen. Some eggs may be carried in the blood stream to the liver, where they
76 remain in the liver tissue.

77 The immunopathological processes around the eggs trapped in the intestinal and hepatic tissues are
78 the basic components of schistosomiasis' pathological development [1]. The pathology results
79 from immune-mediated damage to host cells and tissues. Eggs release enzymes that trigger the
80 formation of granulomas. These granulomas have both a protective and frequently pathological
81 role. Once the granulomas are formed, the excess collagen and other extracellular matrix material
82 deposited around them cause scarring. In the intestines, inflammation may induce diarrhoea,
83 whereas granulomas may cause polyposis with ulcers and recurrent bleeding. In the liver, the scars
84 may disrupt liver function. In severe cases, they can obstruct the portal veins, leading to portal
85 hypertension and, later, to oesophageal varices and then to hematemesis and melena, the main
86 direct causes of death with *S. mansoni* infection. The granulomatous reaction triggered by *S.*
87 *mansoni* infection may lead to splenomegaly, hepatomegaly, liver fibrosis, and ultimately, to
88 accumulation of tissue fluid in the mesenteries and abdominal cavity, known as ascites [2]. Chronic
89 schistosomiasis can lead to anaemia, stunted growth and impairment of cognitive development [3,
90 4]. Many infected people, even those with considerable infection intensity, may remain

91 asymptomatic or experience only non-specific symptoms, such as nausea, headaches, fever, fatigue
92 and abdominal pain [5].

93 In the Democratic Republic of Congo (DRC), little information about the infection burden of
94 schistosomiasis is available and no reports on morbidity due to *S. mansoni* exist. Several studies
95 conducted in neighbouring Uganda, however, show high morbidity and considerable mortality
96 linked to *S. mansoni* infection [2, 6, 7]. In our study, we determined the infection burden of *S.*
97 *mansoni* in Ituri province, DRC, and report on its association with morbidity.

98

99 **Materials and Methods**

100 **Ethics statement**

101 This study was approved by the Swiss Ethical Commission (Ref. No. UBE-15/78) and by the
102 University of Kisangani's Research Ethical Commission, (Ref No: CER/003/GEAK/2016).
103 Research authorization was granted by the Nyankunde Higher Institute of Medical Techniques (Ref
104 No 70/ISTM-N/SGAC/2017), Bunia, DRC. Permission for field work was obtained from the Ituri
105 Provincial Health Division (Ref. 054/433/DPS/IT/06/2016 and Ref. 054/472/DPS/IT/06/2017) and
106 from all relevant health districts. Prior to enrolment, the study objectives and procedures were
107 explained to each participant in the local language and all of their questions were answered. Written
108 informed consent was obtained from all study participants aged 15 years and older. Parents or legal
109 guardians signed consent forms for participants aged <14 years. Participants diagnosed with *S.*
110 *mansoni* were treated with praziquantel (40mg/kg) [8]. All participants received Mebendazole
111 (500mg, single dose, Vermox®) for general deworming, in accordance with the DRC national
112 deworming guidelines.

113 **Study area**

114 The study was conducted in 13 villages in Ituri province, northeastern DRC (geographical
115 coordinates: 1.30°–3.60° latitude and 27.00°–31.40° longitude). Ituri province has an area of about
116 65,658 km² and is home to 5.2 million inhabitants from five different ethnic groups (Nilo-Hamites,
117 Bantu, Nilotic, Sudanese, and Pygmy). The province is bordered by Lake Albert in the east, while
118 several streams and rivers irrigate the province. These waterways are suitable environments for
119 schistosome's intermediate host snails. Schistosomiasis transmission has been documented in the
120 province since colonial times, and mainly occurs along Lake Albert's shores [9]. Only a small

121 proportion of the population residing in Bunia city has access to an adequate water supply. The
122 majority of the population uses natural water bodies (springs, ponds, streams) as its main water
123 source.

124 **Study design and population**

125 We conducted a cross-sectional, household-based, in-depth study of 13 purposively-selected
126 villages across six health districts in Ituri province. The thirteen villages were Bankoko, Lumumba,
127 Simbilyabo, Mangenengene, Kadjugi, Kindia, Gupe, Sukisa, Ngezi, Mambau, Mandima, Pekele,
128 and Ndaru-Muswa. Households were randomly selected in each village and all willing household
129 members aged 6 years and older, and present on the day of the survey were enrolled. Household
130 visitors, as well as mentally and terminally ill persons were excluded.

131 The study incorporated household and individual questionnaires; anthropometric assessments; and
132 parasitological, clinical, and abdominal ultrasonographic examinations.

133 **Procedures**

134 Individual questionnaires

135 All participants were invited to participate in an interview, conducted using a pre-tested
136 questionnaire. This individual questionnaire focused on demographic, anthropometric,
137 occupational, educational and religious characteristics, as well as on knowledge, attitude and
138 practices related to *S. mansoni* infection and disease. The questionnaire also helped to assess for
139 signs and symptoms related to schistosomiasis, such as diarrhoea or blood in the stool in the
140 previous two weeks, and a history of hematemesis at any time, at least once.

141 Anthropometric measurements

142 Participants' height and weight were measured by a Seca analog bathroom scale and height rod,
143 and reported to the nearest half kilogram (0.5 kg) and half centimetre (0.5 cm), respectively.
144 Participants' body mass index (BMI) was also calculated (weight in kilograms divided by the
145 square of the person's height in metres, kg/m²).

146 Parasitological examination

147 Participants were asked to provide one faecal sample (approx. 5 grams of morning stool) in a
148 labelled plastic container for testing with the Kato-Katz technique [10]. From each stool specimen,
149 two thick smears of 41.7 mg [10] were prepared and examined by experienced technicians. To
150 allow for hookworm assessment, all smears were examined by microscope within one hour after
151 preparation. All slides were examined for *S. mansoni* within 24 hours after stool collection. One
152 third of the prepared smears were checked by the principal investigator. All helminth eggs were
153 counted and recorded for each species separately. The intensity of the helminth infection was
154 calculated by multiplying the mean number of eggs found on the two slides by 24. The result was
155 expressed as eggs per gram (EPG) of stool [4].

156 Participants were also asked to provide a urine sample (approx. 60 ml) in a pre-labelled, wide-
157 mouth, plastic container, for the detection of circulating *S. mansoni* antigens using a point-of-care
158 circulating cathodic antigen (POC-CCA) test. Both the stool and urine examinations were
159 performed at the relevant village health centre facility.

160 The POC-CCA tests were performed according to the manufacturer's guidelines (Rapid Medical
161 Diagnostics, Pretoria, South Africa). Urine was examined on the day of collection. In cases where

162 the test was postponed until the next day, urine samples were kept in a solar fridge, at 2–8°C (Steca,
163 Germany). Test results were deemed negative if the POC-CCA band did not appear within 20
164 minutes. Trace, weak, medium and strong coloured CCA bands were recorded as positive results.
165 Questionable results were discussed among at least two technicians and the principal investigator.

166 Clinical examination

167 All participants underwent clinical and abdominal ultrasonography examinations. Clinical
168 examinations consisted of physical examinations performed by an experienced physician and
169 assisted by an experienced nurse.

170 Abdominal ultrasound examination

171 An abdominal ultrasound was performed for each participant, according to a pre-established
172 protocol and using a 1.0 Mhz probe U-Lite Sonoscanner Ultraportable HD Ultrasound Unit (U-
173 Lite, Sonoscanner, 6, Rue André Voguet, Paris, France). A portable generator (MK, China) and
174 solar powered batteries (for remote villages) were used as electricity sources.

175 Participants were examined in a supine position. The size of the left and right liver lobe, the portal
176 vein diameter, and the gall bladder length and width were measured. Organ parenchyma was
177 observed. Liver parenchyma patterns (Figure S1) were assessed following the WHO/TDR
178 guidelines [11]. The length and the width of the spleen were measured and its texture evaluated.

179 **Data management and analysis**

180 Data was entered in Excel and cross-checked against the data sheet. STATA, version 14.2 software
181 (Stata Corp, College Station, USA) was used for data management and analysis. Only participants

182 with a complete dataset were retained in the analysis (Figure 1). Seven age groups were established:
183 (i) 6–9 years, (ii) 10–14 years, (iii) 15–19 years, (iv) 20–29 years, (v) 30–39 years, (vi) 40–49
184 years, and ≥ 50 years. Body mass index (BMI) was calculated and four categories were set:
185 underweight (< 18.5 kg/m²), normal weight (18.5–24.9 kg/m²), overweight (25.0–29.9 kg/m²), and
186 obese (≥ 30 kg/m²). Infection prevalence was expressed as the number of *S. mansoni*-positive
187 individuals divided by the total number of participants examined. Infection intensity was estimated
188 based on helminth egg counts per gram of stool (EPG) when examined with the Kato-Katz
189 technique [10]. *S. mansoni* infection intensities were classified as light (1–99 EPG), moderate
190 (100–399 EPG), and heavy (≥ 400 EPG) [4].

191 Arithmetic mean infection intensity was calculated. Categorical variables were presented as
192 frequencies and percentages. Pearson's chi-square (χ^2) test was used to compare frequency
193 distributions. A univariate logistic regression analysis was carried out to identify associations
194 between *S. mansoni* infection status (outcome) and morbidity indicators (predictors) and/or
195 demographic factors (age, gender). Predictors with a significance level of 20% or less, and age and
196 gender variables were included in the multivariable logistic regression models. Odds ratios (OR),
197 adjusted OR (aOR), and corresponding 95% confidence intervals (95% CI) were calculated. *P*-
198 values < 0.05 were considered statistically significant.


199

200 RESULTS

201 Study population

202 Data were collected between June and September, 2017. We enrolled participants from 13
203 purposely-selected villages across six health districts with an anticipated high prevalence of *S.*
204 *mansoni* infection. Of the 949 individuals enrolled (Figure 1), 586 completed all study procedures
205 and had a complete dataset, that is, one stool sample examined with two Kato-Katz smears, a urine
206 sample tested with POC-CCA, two completed questionnaires, and a clinical and abdominal
207 ultrasound examination.

208 Among those with a complete dataset, 342 (58.4%) were females, 330 (56.3%) were under 20 years
209 of age, and 268 (45.7%) were underweight (Table 1). The prevalence of *S. mansoni* was 59.2%,
210 65.7%, and 76.6% according to Kato-Katz, POC-CCA and combined test results, respectively.
211 Thirty-seven percent, 15.2% and 7.2% of the population had light-, moderate- and heavy-intensity
212 infections, respectively. Infection with soil transmitted helminths (STH) was not common among
213 participants, with only eight participants diagnosed with an STH infection. In contrast, intestinal
214 symptoms were very common, with 52.7%, 23.4% and 21.5%, reporting abdominal pain,
215 diarrhoea, and blood in the stool within the two weeks preceding the survey, respectively. Five
216 participants (0.9%) had experienced hematemesis at least once in his/her life. Abdominal
217 ultrasound examinations revealed that 60.1% of participants had splenomegaly, 23.2% had
218 hepatomegaly, and 0.7% had ascites. Only 47.4% of the participants had a normal liver parenchyma
219 (pattern A).



221 **Figure 1: Flowchart of participant inclusion/exclusion in the 2017 Ituri morbidity study**
 222 **across 13 villages.**

223 **Table 1: Study sample characteristics in the 2017 Ituri infection and morbidity study.** Study
 224 conducted in 13 purposively-selected villages in Ituri province (n=586).

226	Characteristics	N	%
228	Gender		
229	Females	342	58.4
230	Males	244	41.6
231	Age categories (years)		
232	6 – 9	123	21.0
233	10 – 14	140	23.9
234	15 – 19	67	11.4
235	20 – 29	77	13.1
236	30 – 39	68	11.6
237	40 – 49	52	8.9
238	≥50	59	10.1
239	Body mass index (kg/m ² - categories)		
240	Obese (≥30.0)	58	9.9
241	Overweight (25.0–29.9)	24	4.1
242	Normal weight (18.5–24.9)	236	40.3
243	Underweight (<18.5)	268	45.7
244	<i>S. mansoni</i> infection		
245	Kato-Katz test	347	59.2
246	CCA test	385	65.7
247	KK+CCA*	449	76.6
248	Infection intensity (KK only)		
249	Light	216	36.9
250	Moderate	89	15.2
251	Heavy	42	7.2
252	Soil transmitted helminths		
253	<i>Trichuris trichiura</i>	3	0.5
254	<i>Ascaris lumbricoides</i>	1	0.2
255	Hookworm	4	0.7
256	Clinical findings		
257	Diarrhoea	137	23.4
258	Blood in stool	126	21.5
259	Abdominal pain	309	52.7
260	Hematemesis	5	0.9
261	Ultrasound findings		
262	Hepatomegaly (US)	136	23.2
263	Splenomegaly (US)	352	60.1
264	Ascites	4	0.7
265	Pattern A	278	47.4
266	Pattern B/C	214	36.6
267	Pattern D/E	79	13.5
268	Pattern F	15	2.5

270 * KK+CCA, combined any positive result by Kato-Katz and/or by point-of-care circulating
271 cathodic antigen (POC-CCA); KK only, Kato-Katz results only with at least one egg in at least
272 one of two smears.

273 **Morbidity associated with *S. mansoni* infection**

274 The results of the univariable risk analysis are presented in Table 2. Male participants were more
275 likely to be infected with *S. mansoni* but the increased risk was not statistically significant (OR
276 1.22, 95% CI 0.82–1.81, $P=0.318$). *S. mansoni* infection was observed more frequently in younger
277 age groups, with prevalence peaking among young adults (Figure 3). Participants aged 50 years
278 and older had a statistically significant reduced risk of infection compared to children aged 6–9
279 years (Table 2, OR 0.49, 95% CI 0.26–0.92, $P=0.024$).

280 Hookworm infection was negatively associated with *S. mansoni* infection status (OR 0.10, 95% CI
281 0.10–0.98, $P=0.015$). Participants with a normal BMI (OR 2.11, 95% CI 1.14–3.92, $P=0.016$) and
282 underweight individuals (OR 2.31, 95% CI 1.25–4.28, $P=0.006$) had a significantly higher risk of
283 becoming infected with *S. mansoni* than those who were overweight. Study participants who
284 reported an episode of diarrhoea within the preceding two weeks also had an increased risk of
285 receiving an *S. mansoni* diagnosis (OR 1.69, 95% CI 1.03–2.78, $P=0.038$).


286 Diagnosed hepatomegaly (OR 1.67, 95% CI 1.01–2.74, $P=0.042$), splenomegaly (OR 1.50, 95%
287 CI 1.02–2.20, $P=0.040$) and D/E liver parenchyma pattern (OR 1.87, 95% CI 1.04–3.36, $P=0.032$)
288 were significantly associated with an *S. mansoni* infection.

289 The age distribution of reported diarrhoea and blood in stool, as well as the ultrasonographically
290 assessed hepato- and splenomegaly displayed an age distribution resembling the *S. mansoni*
291 infection with peaks in the adolescent and adult age groups (Figure 3).

293 **Table 2: Morbidity associated with *S. mansoni* infection in the 2017 study.** Results of the
 294 univariable analysis of data from 13 purposively-selected villages in Ituri province (n=586).
 295


296	Characteristics	<i>S. mansoni</i> (+)		<i>S. mansoni</i> (-)		OR (95% CI)	p-value
297		<u>N=449</u>		<u>N=137</u>			
298		n	%	n	%		
299	Gender*						
300	Females	257	57.2	85	62.0	1.0	
301	Males	192	42.8	52	38.0	1.22 (0.82–1.81)	0.318
302	Age categories (years)*						
303	6 – 9	92	20.5	31	22.6	1.0	
304	10 – 14	119	26.5	21	15.3	1.61 (0.94–2.76)	0.078
305	15 – 19	54	12.0	13	9.5	1.10 (0.58–2.07)	0.769
306	20 – 29	63	14.0	14	10.2	1.53 (0.81–2.89)	0.184
307	30 – 39	48	10.7	20	14.6	0.77 (0.42–1.42)	0.396
308	40 – 49	35	7.8	17	12.4	0.73 (0.38–1.43)	0.359
309	≥50	38	8.5	21	15.3	0.49 (0.26–0.92)	0.024
310	STH						
311	<i>T. trichiura</i> (Y/N)*	1	0.2	2	1.5	0.15 (0.01–1.69)	0.076
312	<i>A. lumbricoides</i> (Y/N)	1	0.2	0	0.0	na	
313	Hookworm (Y/N)*	4	0.2	3	2.2	0.10 (0.01–0.98)	0.015
314	Anthropometry*						
315	Obese (Y/N)	36	8.0	22	16.1	1.0	
316	Overweight (Y/N)	18	4.0	6	4.4	1.83 (0.62–5.40)	0.264
317	Normal weight (Y/N)	183	40.8	53	38.7	2.11 (1.14–3.92)	0.016
318	Underweight (Y/N)	212	47.2	56	40.9	2.31 (1.25–4.28)	0.006
319	Clinical findings						
320	Diarrhoea (Y/N)*	114	25.4	23	16.8	1.69 (1.03–2.78)	0.038
321	Blood in stool (Y/N)	99	22.1	27	19.7	1.15 (0.72–1.86)	0.560
322	Abdominal pain (Y/N)	238	53.0	71	51.8	1.05 (0.72–1.54)	0.808
323	Hematemesis (Y/N)	4	0.9	1	0.7	1.22 (0.14–11.05)	0.858
324	Ultrasound findings						
325	Hepatomegaly (Y/N)*	113	25.2	23	16.8	1.67 (1.01–2.74)	0.042
326	Splenomegaly (Y/N)*	280	62.4	72	52.6	1.50 (1.02–2.20)	0.040
327	Ascites (Y/N)*	2	0.5	2	1.5	0.30 (0.04–2.17)	0.207
328	Pattern A (Y/N)*	205	45.7	73	53.3	1.0	
329	Pattern B/C (Y/N)	168	37.4	46	33.6	1.00 (0.69–1.46)	0.982
330	Pattern D/E (Y/N)	67	14.9	12	8.8	1.87 (1.04–3.36)	0.032
331	Pattern F (Y/N)	9	2.0	6	4.4	0.48 (0.17–1.38)	0.166

333 * Included in the multivariable analysis. PE, physical examination; US, ultrasound examination;
 334 na, not applicable; Pattern A: normal; Pattern B: “starry sky”; Pattern C: “rings and pipe-stems”;
 335 Pattern DE: “ruff around portal bifurcation and patches”; Pattern F: “bird’s claw” [11].



336

337 **Figure 2: *S. mansoni* infection prevalence by age in the 2017 Ituri province morbidity study**
338 **(n=586).** Overall (green-solid line), female (red-dash line), and male (maroon-long-dash line).
339



340
341 **Figure 3: Age distribution of intestinal and hepatosplenic morbidity in the 2017 Ituri**
342 **province morbidity study (n=586).** Hepatomegaly (olive-solid line), splenomegaly (cranberry-
343 solid line), diarrhoea (magenta-long-dash line), and blood in stool (red-short-dash-dot line).

344
345 Ten variables were included in the multivariable logistic regression analysis, the results of which
346 are displayed in Table 3. Age was negatively associated with *S. mansoni* infection (adjusted odds
347 ratio [aOR] 0.85; 95% CI 0.76–0.94, $P=0.003$) while gender showed no association (aOR 0.95;
348 95% CI 0.66–1.34, $P=0.785$).

349 Of the morbidity indicators investigated, hepatomegaly (aOR 2.04; 95% CI 1.27–3.26, $P=0.003$)
350 and splenomegaly (aOR 1.69; 95% CI 1.17–2.45, $P=0.005$) had highly and statistically significant
351 associations with *S. mansoni* infection. Patients with abnormal liver parenchyma patterns (aOR
352 1.06; 95% CI 0.84–1.34, $P=0.648$) did not have an increased risk for *S. mansoni* infection.

353 The risk analysis considered the results of the Kato-Katz diagnostic tests only. The outcomes of
 354 the risk analysis (Table S1, S2) were largely consistent with those obtained using the combined
 355 diagnostic test results (Kato-Katz and POC-CCA) but there were three differences. First, intestinal
 356 morbidity indicators, such as diarrhoea, were significantly associated with an *S. mansoni* infection
 357 (aOR 1.78, 95% CI 1.14–2.77, $P=0.012$). Second, only hepatomegaly was associated with an *S.*
 358 *mansoni* infection (aOR 1.72, 95% CI 1.10–2.71, $P=0.018$), not splenomegaly (aOR 1.36, 95% CI
 359 0.94–1.95, $P=0.099$). Third, an abnormal liver parenchyma pathology (patterns) was significantly
 360 associated with *S. mansoni* infection (aOR 1.41, 95% CI 1.11–1.78, $P=0.004$).


361 **Table 3. Morbidity associated with *S. mansoni* infection in the 2017 study.** Results of the
 362 multivariable analysis of data from 13 purposively-selected villages in Ituri province (n=586).

Risk factors	aOR (95% CI)	Std. Err.	z	p-value
Demographic risk factors				
Age groups	0.85 (0.76–0.94)	0.047	-3.00	0.003
Gender (Male/Female)	0.95 (0.66–1.38)	0.179	-0.27	0.785
Anthropometric risk factors				
BMI	1.12 (0.92–1.36)	0.113	1.11	0.267
Clinical finding				
Diarrhoea	1.37 (0.88–2.11)	0.303	1.40	0.160
Ultrasound findings				
Hepatomegaly (Yes/No)	2.04 (1.27–3.26)	0.489	2.97	0.003
Splenomegaly (Yes/No)	1.69 (1.17–2.45)	0.320	2.80	0.005
Ascites (Yes/No)	0.55 (0.07–4.48)	0.591	-0.55	0.580
Liver pathology (Yes/No)	1.06 (0.84–1.34)	0.126	0.46	0.648
Co-infection				
<i>Trichuris trichiura</i> (Yes/No)	0.23 (0.02–2.72)	0.290	-1.17	0.244
Hookworm (Yes/No)	0.21 (0.02–2.13)	0.247	-1.32	0.186


386 aOR: adjusted odds ratio in multivariable analysis; CI: confidence interval.

387

388 At the village level, the prevalence of hepatomegaly (Figure 4) and splenomegaly (Figure 5)
389 increased with the prevalence of *S. mansoni* infection. Four patients were diagnosed with ascites;
390 all of whom were residents of villages where overall *S. mansoni* prevalence exceeded 80%.



391
392 **Figure 4: Association of hepatomegaly and *S. mansoni* infection prevalence at village level in**
393 **the 2017 Ituri morbidity study (n=586).**



394
395 **Figure 5: Association of splenomegaly and *S. mansoni* infection prevalence at village level in**
396 **the 2017 Ituri morbidity study (n=586).**

397

398

399 *S. mansoni* infection intensity varied greatly among individuals, with a maximum of 4,497.6 EPG
400 and a mean infection intensity of 109.7 EPG. Table 4 presents the infection intensity according to
401 gender, age, helminth co-infection and morbidity categories. Infection intensity levels were similar
402 in the two gender groups ($P=0.198$). The age distribution of the infection intensity levels followed
403 the age-infection prevalence curve. Heavy-intensity infections were mostly found (12.9%) among
404 adolescents aged 10–14 years ,while no one in the oldest age group (50 years and older) had a
405 heavy-intensity infection ($P=0.006$). Heavy-intensity infections were significantly higher among
406 patients co-infected with *Ascaris lumbricoides* (13.0%, $P=0.005$) and underweight participants
407 (10.1%, $P=0.033$).

408 There was a significantly higher prevalence of reported diarrhoea (40.5%, $P=0.004$) and blood in
409 the stool (52.4%, $P<0.001$) among patients in the heavy-intensity infection group compared to the
410 other infection intensity groups.

411 Among patients with heavy-intensity infections, the prevalence of splenomegaly (81.0%) was
412 significantly higher than among other infection intensity groups ($P=0.008$), while the prevalence
413 of hepatomegaly was similar among all infection intensity groups ($P=0.273$). When stratified by
414 age, patients with an enlarged liver and/or spleen bore a higher infection intensity burden compared
415 to those with a normal-sized liver and spleen in the same age group (Figure 6). In general, younger
416 patients (aged ≤ 19 years) experienced more high-intensity infections compared to those in older
417 age groups (aged ≥ 20 years).


418 **Table 4: *S. mansoni* infection intensity by morbidity in the 2017 study.** Study conducted in 13
 419 purposively-selected villages in Ituri province (n=586). Only results of the Kato-Katz test have
 420 been taken into account in this analysis.

Characteristics		<i>S. mansoni</i> infection intensity								χ^2	p-value
		Negative		Light		Moderate		Heavy			
		n	%	n	%	n	%	n	%		
Overall		239		216		89		42			
Gender											
	Females	152	44.4	117	34.2	50	14.6	23	6.7		
	Males	87	35.7	99	40.6	39	16.0	19	7.8	4.66	0.198
Age categories (years)											
	6 – 9	50	40.7	47	38.2	18	14.6	8	6.5		
	10 – 14	49	35.0	49	35.0	24	17.1	18	12.9		
	15 – 19	19	28.0	25	37.3	17	25.4	6	9.0		
	20 – 29	27	35.0	32	41.6	11	14.3	7	9.1		
	30 – 39	31	45.6	26	38.2	9	13.3	2	2.9		
	40 – 49	27	51.9	18	34.6	6	11.6	1	1.9		
	≥50	36	61.0	19	32.2	4	6.8	0	0.0	36.68	0.006
Soil-transmitted helminths											
	<i>T. trichiura</i> (Y/N)	2	0.8	1	0.5	0	0.0	0	0.0	1.18	0.758
	<i>Ascaris</i> (Y/N)	0	0.0	0	0.0	0	0.0	1	2.4	13.0	0.005
	Hookworm (Y/N)	3	1.3	1	0.5	0	0.0	0	0.0	2.21	0.530
Anthropometry											
	Obese	33	56.9	20	34.5	4	6.9	1	1.7		
	Overweight	13	54.2	9	37.5	2	8.3	0	0.0		
	Normal weight	96	40.7	89	37.7	37	15.7	14	5.9		
	Underweight	97	36.2	98	36.5	46	17.2	27	10.1	18.15	0.033
Clinical findings											
	Diarrhoea (Y/N)	41	17.2	56	25.9	23	25.8	17	40.5	13.11	0.004
	Blood in stool (Y/N)	42	17.6	32	14.8	30	33.7	22	52.4	39.49	<0.001
	Abdom. pain (Y/N)	124	51.9	107	49.5	52	58.4	26	61.9	3.53	0.317
	Hematemesis (Y/N)	3	1.3	1	0.5	1	1.1	0	0.0	1.28	0.733
Ultrasound findings											
	Hepatomegaly (Y/N)	47	19.7	52	24.1	24	27.0	13	31.0	3.89	0.273
	Splenomegaly (Y/N)	134	56.1	124	57.4	60	67.4	34	81.0	11.87	0.008
	Ascites (Y/N)	3	1.3	0	0.0	1	1.1	0	0.0	3.19	0.364
	Pattern A (Y/N)	131	47.1	96	34.5	36	13.0	15	5.4		
	Pattern B (Y/N)	20	33.9	28	47.4	7	11.9	4	6.8		
	Pattern C (Y/N)	60	38.7	56	36.1	26	16.8	13	8.4		
	Pattern D/E (Y/N)	21	26.6	31	39.2	19	24.1	8	10.1		
	Pattern F (Y/N)	7	46.7	5	33.3	1	6.7	2	13.3	19.74	0.072

461 Pattern A: normal; Pattern B: “starry sky”; Pattern C: “rings and pipe-stems”; Pattern DE: “ruff
 462 around portal bifurcation and patches”; Pattern F: “bird’s claw”. [Ref.]

463 *S. mansoni* infection intensity varied considerably among patients with different liver parenchyma
464 pathologies. In general, more heavy-intensity infections were observed among patients with more
465 severe liver morbidity patterns. That is, the number of individuals with heavy-intensity infections
466 increased with the severity of the liver parenchyma pattern, from normal liver parenchyma pattern
467 A (5.4%) to the most severe “bird’s claw” pattern F (13.3%). The association was borderline
468 significant ($P=0.072$). When stratified by age, a clear association emerged between increased
469 number of high-intensity infections and increasingly abnormal liver pathologies (Figure 7). Liver
470 parenchyma worsened, from normal pattern A to pattern DE, the median infection intensity
471 increased. Patients with pattern F had similar- or lower-intensity infections than patients with less
472 severe morbidity patterns.

473




474

475

476 **Figure 6: *S. mansoni* infection intensity by hepatomegaly and splenomegaly and age in the**
477 **2017 Ituri morbidity study (n=586). Hepatomegaly (brown) and splenomegaly (cranberry).**

478



479
480

481 **Figure 7: *S. mansoni* infection intensity by liver parenchyma patterns and age in the 2017**
482 **Ituri morbidity study (n=586).** Pattern A: normal (lime); Pattern B/C (magenta): “starry sky” and
483 “rings and pipe-stems”; Pattern D/E (red): “ruff and patches around portal bifurcation”; Pattern F
484 (orange): “bird’s claw”.

485
486

487 **Discussion**

488 Today, the World Health Organisation's recommended control strategy for schistosomiasis focuses
489 on controlling morbidity, with preventive chemotherapy being a key concept. The aim is to prevent
490 morbidities from developing by regularly treating the exposed population, and thereby avoiding
491 the development of severe infection intensities and hence, morbidity. Regular mass-drug
492 administration is the recommended control activity [12].

493 Although minimizing morbidity is the target of schistosomiasis control efforts, control programmes
494 rarely collect (baseline) and monitor morbidity data. Instead, they largely rely on monitoring
495 infection intensities, which are linked to morbidity and much easier to assess than intestinal and
496 hepatosplenic morbidity. Consequently, little is known about the morbidity burden of
497 schistosomiasis.

498 In this study, we assessed the magnitude of the intestinal and hepatosplenic morbidity burden in
499 Ituri province, DRC, and investigated its associations with *S. mansoni* infection status. To that end,
500 we conducted a cross-sectional study in 13 *S. mansoni* endemic villages. We enrolled all household
501 member six years and older, and assessed their *S. mansoni* infection status and their intestinal and
502 hepatosplenic morbidity.

503 We found a high degree of intestinal and hepatosplenic morbidity. About one quarter of the study
504 participants reported diarrhoea (23.4%) and blood in the stool (21.5%). Upon ultrasonography
505 examination, almost one-quarter was diagnosed with hepatomegaly (23.2%); almost two-thirds
506 (60.1%) had splenomegaly, and more than half (52.6%) had abnormal liver parenchyma (pattern
507 B–F). Five patients reported an experience of hematemesis and four patients had ascites.

508 In our study population, we found a high prevalence of *S. mansoni* infection (76.6%). Light-,
509 moderate- and heavy-intensity infections were diagnosed in high frequencies of 36.9%, 15.2% and
510 7.2%, respectively. *S. mansoni* infection prevalence and intensity was highest in the adolescent and
511 young adult age groups. The prevalence of intestinal and hepatosplenic morbidity indicators
512 showed a very similar age distribution (although hepato- and splenomegaly peaked in older age
513 groups), and at village level, hepatosplenic morbidity prevalence increased with infection
514 prevalence. Both observations suggesting a close link between morbidity and *S. mansoni* infection.
515 Furthermore, at individual level, we found an increased risk of hepatomegaly and splenomegaly in
516 *S. mansoni*-infected patients, confirming the association found at village level and the similarly
517 shaped age distributions. The findings are also consistent with documented hepatosplenic
518 morbidity associated with *S. mansoni* infection [13, 14]. Hence, providing further evidence that *S.*
519 *mansoni* infection is a major contributor to the overall observed morbidity.

520 We found three notable differences in the risk results when relying on the diagnostic results from
521 the Kato-Katz technique only. First, reported diarrhoea was significantly associated with *S.*
522 *mansoni* infection; second, pathological changes of the liver parenchyma were associated with *S.*
523 *mansoni* infection as was hepatomegaly; and, third, splenomegaly was not associated with *S.*
524 *mansoni* infection. Using the Kato-Katz technique alone to diagnose *S. mansoni* infection reduces
525 the overall sensitivity of the diagnostic approach due to the low sensitivity of the technique itself
526 [15, 16]. Hence, on average, those diagnosed with an *S. mansoni* infection are more likely to have
527 a higher infection intensity in comparison to the combined diagnostic approach. From these
528 observations, we see that subtle morbidity increases — such as reported diarrhoea and pathological
529 changes in the liver parenchyma — become statistically significant. Indeed, for both morbidity
530 indicators, we observed an association with *S. mansoni* infection intensity. Patients with diarrhoea

531 had the highest prevalence of heavy-intensity infections (Table 2) and those with abnormal liver
532 parenchyma patterns D–E had the highest mean infection intensities (Figure 4).

533 Quantifying schistosomiasis morbidity is a challenging [17, 18] and controversial matter [19].
534 Morbidity associated with *Schistosoma* infection is unspecific. Hence, the observed morbidity
535 pattern might be provoked partially by or in combination with other pathogens, such as other
536 helminth species, protozoa, bacteria and viruses. Given that multiple infections are frequent in
537 tropical Africa, a combination of infections is most likely responsible for the observed morbidity.
538 In Ituri province, other parasitic infections, such as malaria (i.e. *Plasmodium falciparum*), and other
539 infections with hepatosplenic affinity, such as viral hepatitis, are prevalent [2, 6, 20, 21] and may
540 have contributed to the hepatosplenic morbidity pattern observed. The time gap between infection
541 and the occurrence of measurable morbidity further complicates efforts to assess the association
542 between infection and morbidity. Furthermore, organomegaly is sometimes described as normally
543 present in children; it then regresses and disappears in adulthood [2, 22-24].

544 In our study, we encountered patients with severe complications from *S. mansoni* infection, which
545 further underscore the importance of the infection’s morbidity burden. Four people (0.9%) reported
546 a history of hematemesis. The finding appears to corroborate the health service’s statistics report
547 from the Angumu health district (on the shore of Lake Albert), which declares that hematemesis is
548 a frequent medical emergency and that adults have died after vomiting blood in this area.
549 Oesophageal varices remain silent until they rupture and irreversible damage occurs [21]. Angumu
550 health district is a remote area and well known for its high blood transfusion rates. Patients
551 vomiting blood often reach the hospital too late, leading to the worst medical outcome.

552 The morbidity levels we observed are consistent with those measured by Ongom and Bradley [7],
553 who found serious morbidity, including diarrhoea and abdominal pain, in a schistosomiasis
554 endemic community on Lake Albert in Uganda. Other studies of *S. mansoni* endemic communities
555 outside of the DRC present similar morbidity levels [24-26]. Very few studies of morbidity due to
556 schistosome infection in DRC exist [21, 27]. Our study contributes to the country's knowledge
557 base and may offer a baseline for future intervention studies to determine the exact extent of
558 morbidity associated with *S. mansoni* infection.

559 We conducted our study in purposively-sampled villages known to have a high prevalence of *S.*
560 *mansoni*. Thus, the examined population is not representative of the entire province but rather of
561 high transmission areas. Furthermore, ongoing civil unrest in Ituri province creates a challenging
562 security situation, which only afforded us a short time in each village. For this reason, only one
563 stool sample could be collected from each study participant. Finally, limited available resources
564 did not allow us to examine participants for parasitic, bacterial and viral co-infections, which could
565 have helped to better explain the degree of morbidity linked to *S. mansoni* infection.

566 Our study provides, for the first time, comprehensive baseline data showing a high intestinal and
567 hepatosplenic morbidity burden in Ituri province; a burden that is associated with *S. mansoni*
568 infection at both the individual and community level. At present, we cannot quantify the extent to
569 which *S. mansoni* infection alone is responsible for the observed morbidity (or whether other
570 infections contribute). To answer this question, additional investigations are needed. However, the
571 high degree of intestinal and hepatosplenic morbidity present in Ituri province warrants immediate
572 and comprehensive control activities.

573 **Acknowledgements**

574 We are grateful to all the study participants both in 2016 and in 2017. Our sincere thanks
575 to the research teams in this two-years period. We thank the Provincial Health Division officers,
576 all the Health Districts officers, and the Institut Supérieur des Techniques Médicales de Nyankunde
577 staff for their support and the local authorities for their support during the fieldwork.

578

579

580 References

- 581
- 582 1. Loker ES, Hofkin BV. Parasite Versus Host: Pathology and Disease. *Parasitology: A Conceptual*
- 583 *Approach*. 2015:159-92.
- 584 2. Kabatereine NB, Kemijumbi J, Ouma JH, Kariuki HC, Richter J, Kadzo H, et al. Epidemiology and
- 585 morbidity of *Schistosoma mansoni* infection in a fishing community along Lake Albert in Uganda. *T*
- 586 *Roy Soc Trop Med H*. 2004;98(12):711-8.
- 587 3. Savioli L, Albonico M, Engels D, Montresor A. Progress in the prevention and control of schistosomiasis
- 588 and soil-transmitted helminthiasis. *Parasitol Int*. 2004;53(2):103-13.
- 589 4. Savioli L, Stansfield S, Bundy DAP, Mitchell A, Bhatia R, Engels D, et al. Schistosomiasis and soil-
- 590 transmitted helminth infections: forging control efforts. *T Roy Soc Trop Med H*. 2002;96(6):577-9.
- 591 5. Gray DJ, Ross AG, Li YS, McManus DP. CLINICAL REVIEW Diagnosis and management of
- 592 schistosomiasis. *Brit Med J*. 2011;342.
- 593 6. Tukahebwa EM, Magnussen P, Madsen H, Kabatereine NB, Nuwaha F, Wilson S, et al. A Very High
- 594 Infection Intensity of *Schistosoma mansoni* in a Ugandan Lake Victoria Fishing Community Is Required
- 595 for Association with Highly Prevalent Organ Related Morbidity. *Plos Neglect Trop D*. 2013;7(7).
- 596 7. Ongom VL, Owor R, Grundy R, Bradley DJ. Epidemiology and Consequences of *Schistosoma-Mansoni*
- 597 *Infection in West Nile, Uganda* .2. Hospital Investigation of a Sample from Panyagoro Community. *T*
- 598 *Roy Soc Trop Med H*. 1972;66(6):852-63.
- 599 8. WHO. Preventive chemotherapy in human helminthiasis. 2006.
- 600 9. WHO. Les bilharzioses humaines au Congo Belge et au Ruanda-Urundi. 1954.
- 601 10. Katz N, Chaves A, Pellegrino J. A simple device for quantitative stool thick-smear technique in
- 602 *Schistosomiasis mansoni*. *Rev Inst Med Trop Sao Paulo*. 1972;14(6):397-400.
- 603 11. Richter J, Domingues ALC, Barata CH, Prata AR, Lambertucci JR. Report of the second satellite
- 604 symposium on ultrasound in schistosomiasis. *Mem I Oswaldo Cruz*. 2001;96:151-6.
- 605 12. Ross AGP, Li YS. Mass Drug Administration (MDA) for Schistosomiasis Reply. *J Infect Dis*.
- 606 2015;211(5):849-
- 607 13. Kaatano GM, Min D-Y, Siza JE, Yong T-S, Chai J-Y, Ko Y, et al. *Schistosoma mansoni*-Related
- 608 Hepatosplenic Morbidity in Adult Population on Kome Island, Sengerema District, Tanzania. *Korean J*
- 609 *Parasitol*. 2015;53(5):545-51.
- 610 14. Booth M, Vennervald BJ, Kabatereine NB, Kazibwe F, Ouma JH, Kariuki CH, et al. Hepatosplenic
- 611 morbidity in two neighbouring communities in Uganda with high levels of *Schistosoma mansoni*
- 612 infection but very different durations of residence. *T Roy Soc Trop Med H*. 2004;98(2):125-36.
- 613 15. Maurice Mutro Nigo GBS-B, Manuel Battegay, Peter Odermatt, Patrick Hunziker. Schistosomiasis:
- 614 from established diagnostic assays to emerging micro/nanotechnology-based rapid field testing for
- 615 clinical management and epidemiology. *Prec Nanomed*. 2020;3(1):439-58.
- 616 16. Mazigo HD, Heukelbach J. Diagnostic Performance of Kato Katz Technique and Point-of-Care
- 617 Circulating Cathodic Antigen Rapid Test in Diagnosing *Schistosoma mansoni* Infection in HIV-1 Co-
- 618 Infected Adults on the Shoreline of Lake Victoria, Tanzania. *Tropical medicine and infectious disease*.
- 619 2018;3(2).
- 620 17. Samuels AM, Matey E, Mwinzi PNM, Wiegand RE, Muchiri G, Ireri E, et al. *Schistosoma mansoni*
- 621 morbidity among school-aged children: a SCORE project in Kenya. *The American journal of tropical*
- 622 *medicine and hygiene*. 2012;87(5):874-82.
- 623 18. van der Werf MJ, de Vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, Habbema JD, et al. Quantification
- 624 of clinical morbidity associated with schistosome infection in sub-Saharan Africa. *Acta Trop*.
- 625 2003;86(2-3):125-39. Epub 2003/05/15.

- 626 19. Asztely MS, Eriksson B, Gabone RM, Nilsson LA. Is ultrasonography useful for population studies on
627 schistosomiasis mansoni? An evaluation based on a survey on a population from Kome Island,
628 Tanzania. *Acta Radiol Open*. 2016;5(12):2058460116686392. Epub 2017/03/14.
- 629 20. Davis SM, Wiegand RE, Mulama F, Kareko EI, Harris R, Ochola E, et al. Morbidity associated with
630 schistosomiasis before and after treatment in young children in Rusinga Island, western Kenya. *Am J*
631 *Trop Med Hyg*. 2015;92(5):952-8. Epub 2015/03/12.
- 632 21. Gryseels B, Polderman AM. The Morbidity of Schistosomiasis-Mansoni in Maniema (Zaire). *T Roy Soc*
633 *Trop Med H*. 1987;81(2):202-9.
- 634 22. Gryseels B. Morbidity and Dynamics of Schistosomiasis after Chemotherapy - Implications for Control.
635 *Eur J Pharmacol*. 1990;183(3):670-.
- 636 23. Gryseels B, Nkulikyinka L. The Morbidity of Schistosomiasis-Mansoni in the Highland Focus of Lake
637 Cohoha, Burundi. *T Roy Soc Trop Med H*. 1990;84(4):542-7.
- 638 24. Abdel-Wahab MF, Esmat G, El-Boraey Y, Ramzy I, Medhat E, Strickland GT. The epidemiology of
639 schistosomiasis in Egypt: Methods, training, and quality control of clinical and ultrasound
640 examinations. *Am J Trop Med Hyg*. 2000;62(2):17-20.
- 641 25. El-Hawey AM, Amr MM, Abdel-Rahman AH, El-Ibiary SA, Agina AM, Abdel-Hafez MA, et al. The
642 epidemiology of schistosomiasis in Egypt: Gharbia Governorate. *Am J Trop Med Hyg*. 2000;62(2
643 Suppl):42-8.
- 644 26. El-Khoby T, Galal N, Fenwick A, Barakat R, El-Hawey A, Nooman Z, et al. The epidemiology of
645 schistosomiasis in Egypt: summary findings in nine governorates. *Am J Trop Med Hyg*. 2000;62(2
646 Suppl):88-99.
- 647 27. Gryseels B, Polderman AM. Schistosoma-Mansoni Morbidity in 3 Central-Africa Foci - Intrapopulation
648 Vs Interpopulation Analysis. *Trop Med Parasitol*. 1987;38(3):263-.

649

650

651

652 **Funding**

653 The study was funded by private funds (Poverty Fund, Switzerland). The funders had no role in
654 study design, data collection and data analysis, decision to publish, or preparation of the
655 manuscript.

656

657 **Competing interest**

658 No authors have competing interests.

659

660 **Supplementary information captions**

661 **Tables**

662

663 **Table S1: Univariable associations with *S. mansoni* infection in the 2017 morbidity study.**

664 Study conducted in 13 purposively-selected villages in Ituri province (n=586). Only
665 diagnostic results of Kato-Katz (KK) test have been taken into account.

666

667 **Table S2: Risk factors for morbidity due to *Schistosoma mansoni* infection, 2017 study.**

668 Results of the multivariable analysis of risk factors for morbidity due to *Schistosoma*
669 *mansoni* infection among participants from 13 villages in Ituri province (n=586).
670 Only diagnostic results of Kato-Katz (KK) test have been taken into account.

671

672 **Figures**

673

674 **Figure S1:** Liver image patterns associated with schistosomiasis, by [11].